Local Institution

San Miguel de Tucumán, Tucumán Province T4000JCU

0 studies enrolling now · 17 studies all time

What they study most

Acute Coronary Syndrome, Atrial Fibrillation, Breast Cancer, Cancer, Leukemia, Lung Cancer - Non Small Cell Squamous, Melanoma, Prostate Cancer, Prostatic Neoplasms, Pulmonary Embolism, Rheumatoid Arthritis, Rheumatoid Arthritis (RA)

Studies at this site

• Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate — Completed
• Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer — Completed
• Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin — Completed
• Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab — Completed
• A Phase III Study of Apixaban in Patients With Atrial Fibrillation — Completed
• Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) — Stopped early
• Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer — Completed
• Study of Immunotherapy to Treat Advanced Prostate Cancer — Completed
• Expanded Access Program With Nivolumab to Treat Melanoma — NO_LONGER_AVAILABLE
• Phase III Acute Coronary Syndrome — Stopped early
• Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness — Completed
• Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe — Completed
• Methotrexate-Inadequate Response Study — Completed
• Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis — Completed
• Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis — Completed
• Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis — Stopped early
• Abatacept Versus Adalimumab Head-to-Head — Completed